Satralizumab's MOGAD Bid: First-Mover Advantage Meets Unresolved Evidence Gaps

FDA Grants Priority Review for Enspryng in MOGAD

Roche announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). This decision is based on positive results from the Phase III METEOROID study, which demonstrated that Enspryng significantly reduced the risk of MOGAD relapses by 68% compared to placebo. If approved, Enspryng would be the first disease-modifying therapy for MOGAD, a rare and debilitating autoimmune disease of the central nervous system with no currently approved treatments. The FDA is expected to make an approval decision by January 10, 2027.

• The Phase III METEOROID study met its primary endpoint, showing that Enspryng significantly reduced the risk of a new MOGAD relapse by 68% compared to placebo (p=0.0025). At 48 weeks, 87% of Enspryng-treated patients remained relapse-free, compared to 67% in the placebo arm. The study also demonstrated significant improvements in key secondary measures, including annualised relapse rate, MRI lesion activity, and rescue therapy use.
• The FDA's Priority Review designation for Enspryng in MOGAD underscores the urgent unmet medical need for this rare autoimmune disease, which currently lacks approved treatments. This marks the second FDA Priority Review for Enspryng in 2026, following one for thyroid eye disease. Additionally, the European Medicines Agency (EMA) has validated the application for Enspryng for MOGAD in Europe, with a decision expected in Q3 2027.
• Enspryng (satralizumab) is a humanised monoclonal antibody developed by Chugai, a member of the Roche Group, that targets the interleukin-6 (IL-6) receptor. It utilizes novel recycling antibody technology to provide sustained IL-6 inhibition, rapidly and consistently suppressing inflammatory pathways. The safety profile observed in the METEOROID study was consistent with over a decade of Enspryng's clinical trial and post-approval experience in neuromyelitis optica spectrum disorder (NMOSD).

Addressing the Significant Unmet Need in MOGAD

Despite growing clinical experience with MOGAD, the treatment landscape remains characterized by significant evidence gaps, heterogeneous practice patterns, and unresolved questions around patient selection and therapeutic sequencing. The absence of robust, prospective comparative data continues to limit the ability of clinical and strategic teams to draw definitive conclusions about optimal management.

• Lack of consensus on maintenance therapy initiation and agent selection. Whether to initiate long-term immunotherapy after a first event — particularly in patients with incomplete recovery — remains controversial. A 2025 review notes there is no consensus on the optimal therapeutic strategy, treatment duration, or which patients may benefit most from prolonged immunosuppression. Survey data from 346 neurologists confirm substantial variability: 56.6% of non-neuroimmunologists chose to initiate maintenance therapy after a first episode, compared with only 18.9% of neuroimmunologists.

• Absence of large randomized controlled trials. Across multiple analyses, the evidence base for MOGAD maintenance therapies — including rituximab (RTX), mycophenolate mofetil (MMF), and azathioprine (AZA) — rests on retrospective, observational, or single-center data. A 2022 meta-analysis of 346 patients and a 2020 multicenter retrospective study both explicitly call for prospective randomized controlled studies to validate their findings. Similarly, a 2025 comparative study of tocilizumab and rituximab concludes that "larger randomized-controlled trials are warranted."

• Variable and unpredictable disease course. While some patients follow a monophasic course, up to 50% may relapse, and there are no reliable predictors of recurrence. This clinical heterogeneity complicates both trial design and individualized treatment planning.

• Suboptimal relapse prevention across available agents. Even on maintenance immunotherapy, relapse rates remain high for several agents: mycophenolate mofetil was associated with relapse in 74% of patients (ARR 0.67), rituximab in 61% (ARR 0.59), and azathioprine in 59% (ARR 0.2). All 9 patients treated with multiple sclerosis disease-modifying agents experienced a breakthrough relapse on treatment (ARR 1.5), suggesting these agents are ineffective in MOGAD.

• Corticosteroid regimen optimization at onset. The dose and duration of oral corticosteroids at disease onset influences time to first relapse, yet practice is inconsistent. A 2024 multicenter cohort study identified an optimal dose of 12.5 mg of prednisone daily in adults for a minimum of 3 months, associated with an 88% reduction in relapse risk compared with those never treated in this range — yet this regimen is not uniformly applied.

• Serological diagnostic challenges complicating treatment decisions. Not all laboratories use standardized methods for MOG-IgG detection, and the interpretation of low or borderline antibody titers remains debated. The prognostic value of serial antibody testing is also unclear, adding uncertainty to decisions about initiating or continuing immunotherapy.

• Limited options for refractory or highly relapsing patients. For patients who fail multiple lines of therapy, the evidence base is sparse. Tocilizumab has shown promise in highly relapsing MOGAD patients with inadequate response to IVIG, with all four patients in one case series remaining relapse-free at a median follow-up of 25.0 months — but this represents preliminary, single-center data requiring broader validation.

METEOROID Study: Enspryng's Efficacy and Safety Profile

Several key studies have examined MOGAD across distinct clinical questions — relapse prevention, antibody dynamics, and quality of life — each with differing designs, populations, and endpoints. The table below summarizes the study design parameters and primary endpoints from the relevant trials and studies identified in the literature.

The knowledge base does not have sufficient information on this aspect.

Note: The section header references "METEOROID Study: Enspryng's Efficacy and Safety Profile." No data pertaining to a study by that name or to Enspryng (satralizumab) specifically in MOGAD was identified in the available literature; the table above reflects all MOGAD-relevant study design and endpoint data present in the retrieved sources.

Enspryng's Expanding Role Beyond MOGAD

Beyond its approved indication in AQP4-IgG-seropositive NMOSD, satralizumab is being investigated across additional neuroinflammatory indications. Two distinct clinical programmes — one in AQP4-IgG-seropositive NMOSD (post-marketing) and one in autoimmune encephalitis — reflect the broadening clinical ambition for this IL-6 receptor-targeting monoclonal antibody.

A New Horizon for MOGAD Treatment

The FDA's decision to grant Priority Review for Enspryng (satralizumab) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) signals a profound shift in the therapeutic landscape for this often-misunderstood and debilitating condition. For too long, patients with MOGAD have navigated a treatment void, relying on broad immunosuppressants or empirical approaches due to the absence of any approved disease-modifying therapies. This lack of targeted options has underscored a significant unmet medical need, particularly given that MOGAD is increasingly recognized as a distinct autoimmune central nervous system disorder, separate from conditions like neuromyelitis optica spectrum disorder (NMOSD).

The positive Phase III METEOROID study results, showing a substantial 68% reduction in MOGAD relapses, provide compelling evidence for satralizumab's potential to become the first dedicated treatment. This not only offers hope for improved patient outcomes but also validates the interleukin-6 (IL-6) pathway as a critical therapeutic target in MOGAD, building on the drug's established role in AQP4-IgG+ NMOSD.

Strategically, this move allows Roche to:

• Solidify market leadership: By securing a first-in-class approval, Enspryng will define the initial standard of care for MOGAD, leveraging its existing brand recognition.

• Maximize asset value: Expanding the label of an already approved drug into a new, high-need indication extends its commercial lifecycle and strengthens its overall market position.

However, the path forward is not without considerations. While Enspryng may be the first, other IL-6 receptor inhibitors, such as tocilizumab, have shown promising efficacy in observational studies for MOGAD, suggesting potential future competition or off-label use. Furthermore, the inherent challenges in accurately diagnosing MOGAD, given its broad clinical spectrum and the need to differentiate it from other demyelinating diseases, could impact the speed and breadth of adoption. Clinicians will also be keen to see more detailed long-term efficacy and safety data specifically from the METEOROID study for the MOGAD population, even with satralizumab's established safety profile in NMOSD. Ultimately, this Priority Review represents a critical step towards a more precise, targeted, and hopeful future for individuals living with MOGAD.